Harpoon Therapeutics Inc., a clinical-stage immunotherapy company developing a novel class of T cell engagers, has appointed Karin Ann Thacker, M.Sc., as vice president, regulatory affairs and quality assurance. Thacker joins Harpoon from Gritstone Oncology where she most recently served as vice president, global regulatory affairs.   “I am pleased to welcome Karin Thacker to Harpoon’s executive management team to oversee our global regulatory affairs and quality assurance efforts,” said Gerald ...